Antitumor activity of α‐pinene in T‐cell tumors
T‐cell acute leukemia and lymphoma have a poor prognosis. Although new therapeutic agents have been developed, their therapeutic effects are suboptimal. α‐Pinene, a monoterpene compound, has an antitumor effect on solid tumors; however, few comprehensive investigations have been conducted on its imp...
Saved in:
Published in | Cancer science Vol. 115; no. 4; pp. 1317 - 1332 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
John Wiley and Sons Inc
01.04.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | T‐cell acute leukemia and lymphoma have a poor prognosis. Although new therapeutic agents have been developed, their therapeutic effects are suboptimal. α‐Pinene, a monoterpene compound, has an antitumor effect on solid tumors; however, few comprehensive investigations have been conducted on its impact on hematologic malignancies. This report provides a comprehensive analysis of the potential benefits of using α‐pinene as an antitumor agent for the treatment of T‐cell tumors. We found that α‐pinene inhibited the proliferation of hematologic malignancies, especially in T‐cell tumor cell lines EL‐4 and Molt‐4, induced mitochondrial dysfunction and reactive oxygen species accumulation, and inhibited NF‐κB p65 translocation into the nucleus, leading to robust apoptosis in EL‐4 cells. Collectively, these findings suggest that α‐pinene has potential as a therapeutic agent for T‐cell malignancies, and further investigation is warranted.
α‐Pinene inhibited the proliferation of T‐cell tumor cell lines, induced mitochondrial dysfunction and reactive oxygen species accumulation, and inhibited NF‐κB p65 translocation into the nucleus, leading to robust apoptosis in tumor cells. |
---|---|
AbstractList | Abstract
T‐cell acute leukemia and lymphoma have a poor prognosis. Although new therapeutic agents have been developed, their therapeutic effects are suboptimal. α‐Pinene, a monoterpene compound, has an antitumor effect on solid tumors; however, few comprehensive investigations have been conducted on its impact on hematologic malignancies. This report provides a comprehensive analysis of the potential benefits of using α‐pinene as an antitumor agent for the treatment of T‐cell tumors. We found that α‐pinene inhibited the proliferation of hematologic malignancies, especially in T‐cell tumor cell lines EL‐4 and Molt‐4, induced mitochondrial dysfunction and reactive oxygen species accumulation, and inhibited NF‐κB p65 translocation into the nucleus, leading to robust apoptosis in EL‐4 cells. Collectively, these findings suggest that α‐pinene has potential as a therapeutic agent for T‐cell malignancies, and further investigation is warranted. T‐cell acute leukemia and lymphoma have a poor prognosis. Although new therapeutic agents have been developed, their therapeutic effects are suboptimal. α‐Pinene, a monoterpene compound, has an antitumor effect on solid tumors; however, few comprehensive investigations have been conducted on its impact on hematologic malignancies. This report provides a comprehensive analysis of the potential benefits of using α‐pinene as an antitumor agent for the treatment of T‐cell tumors. We found that α‐pinene inhibited the proliferation of hematologic malignancies, especially in T‐cell tumor cell lines EL‐4 and Molt‐4, induced mitochondrial dysfunction and reactive oxygen species accumulation, and inhibited NF‐κB p65 translocation into the nucleus, leading to robust apoptosis in EL‐4 cells. Collectively, these findings suggest that α‐pinene has potential as a therapeutic agent for T‐cell malignancies, and further investigation is warranted. α‐Pinene inhibited the proliferation of T‐cell tumor cell lines, induced mitochondrial dysfunction and reactive oxygen species accumulation, and inhibited NF‐κB p65 translocation into the nucleus, leading to robust apoptosis in tumor cells. T-cell acute leukemia and lymphoma have a poor prognosis. Although new therapeutic agents have been developed, their therapeutic effects are suboptimal. α-Pinene, a monoterpene compound, has an antitumor effect on solid tumors; however, few comprehensive investigations have been conducted on its impact on hematologic malignancies. This report provides a comprehensive analysis of the potential benefits of using α-pinene as an antitumor agent for the treatment of T-cell tumors. We found that α-pinene inhibited the proliferation of hematologic malignancies, especially in T-cell tumor cell lines EL-4 and Molt-4, induced mitochondrial dysfunction and reactive oxygen species accumulation, and inhibited NF-κB p65 translocation into the nucleus, leading to robust apoptosis in EL-4 cells. Collectively, these findings suggest that α-pinene has potential as a therapeutic agent for T-cell malignancies, and further investigation is warranted. |
Author | Kimura, Maiko Matsuda, Masayuki Asada, Noboru Fukui, Chie Ono, Mitsuaki Moriyama, Takashi Takarada, Takeshi Matsumura, Akifumi Miyake, Masayuki Yamada, Daisuke Aoe, Michinori Kitamura, Wataru Abe, Masaya Maeda, Yoshinobu Wang, Ziyi |
AuthorAffiliation | 6 Division of Medical Support Okayama University Hospital Okayama Japan 2 Department of Hematology and Oncology Okayama University Hospital Okayama Japan 4 Department of Regenerative Science Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan 5 Department of Molecular Biology and Biochemistry Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan 1 Department of Hematology, Oncology and Respiratory Medicine Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan 3 Division of Hematology, Department of Medicine Kobe University Hospital Kobe Japan |
AuthorAffiliation_xml | – name: 5 Department of Molecular Biology and Biochemistry Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan – name: 1 Department of Hematology, Oncology and Respiratory Medicine Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan – name: 3 Division of Hematology, Department of Medicine Kobe University Hospital Kobe Japan – name: 6 Division of Medical Support Okayama University Hospital Okayama Japan – name: 2 Department of Hematology and Oncology Okayama University Hospital Okayama Japan – name: 4 Department of Regenerative Science Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan |
Author_xml | – sequence: 1 givenname: Masaya surname: Abe fullname: Abe, Masaya organization: Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences – sequence: 2 givenname: Noboru orcidid: 0000-0001-7322-5460 surname: Asada fullname: Asada, Noboru email: nasada@okayama‐u.ac.jp organization: Okayama University Hospital – sequence: 3 givenname: Maiko surname: Kimura fullname: Kimura, Maiko organization: Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences – sequence: 4 givenname: Chie surname: Fukui fullname: Fukui, Chie organization: Kobe University Hospital – sequence: 5 givenname: Daisuke surname: Yamada fullname: Yamada, Daisuke organization: Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences – sequence: 6 givenname: Ziyi surname: Wang fullname: Wang, Ziyi organization: Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences – sequence: 7 givenname: Masayuki surname: Miyake fullname: Miyake, Masayuki organization: Okayama University Hospital – sequence: 8 givenname: Takeshi surname: Takarada fullname: Takarada, Takeshi organization: Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences – sequence: 9 givenname: Mitsuaki surname: Ono fullname: Ono, Mitsuaki organization: Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences – sequence: 10 givenname: Michinori surname: Aoe fullname: Aoe, Michinori organization: Okayama University Hospital – sequence: 11 givenname: Wataru surname: Kitamura fullname: Kitamura, Wataru organization: Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences – sequence: 12 givenname: Masayuki surname: Matsuda fullname: Matsuda, Masayuki organization: Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences – sequence: 13 givenname: Takashi surname: Moriyama fullname: Moriyama, Takashi organization: Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences – sequence: 14 givenname: Akifumi surname: Matsumura fullname: Matsumura, Akifumi organization: Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences – sequence: 15 givenname: Yoshinobu surname: Maeda fullname: Maeda, Yoshinobu organization: Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38279512$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kDtOwzAYgC1URB8wcAGUEYaU345rJxOqKl5SJQbKbCV-gFHqlDgp6sYRuAoX4RCchLQpFQx4sS1_-mx_fdRxhdMIHWMY4macy9QPMYOY7aEejmgScgDW2ax5mEBEuqjv_TNAxGhCD1A3iglPRpj0EB27ylb1vCiDVFZ2aatVUJjg8-Pr7X1hnXY6sC6YNTup8zzYkP4Q7Zs09_poOw_Qw9XlbHITTu-ubyfjaSgpARYaLoHLiGpCpMwY4YQZGcuMcyVVRilIjY0yAIpk3CgCGYl1opSmakRxaqIBumi9izqbayW1q8o0F4vSztNyJYrUir8nzj6Jx2IpMAZoGsSN4XRrKIuXWvtKzK1f_yR1uqi9IAlJgLGY8wY9a1FZFt6X2uzuwSDWmUWTWWwyN-zJ74ftyJ-uDXDeAq8216v_TWIyvm-V3z_njIE |
Cites_doi | 10.1016/S1470-2045(16)30167-X 10.1080/13880209.2017.1309555 10.1269/jrr.10151 10.1158/0008-5472.CAN-08-1490 10.3390/molecules24152683 10.1111/cas.13792 10.1038/onc.2013.565 10.1371/journal.pone.0000693 10.1021/jf901162f 10.1038/nature04870 10.1016/j.jphs.2015.01.008 10.1146/annurev.immunol.021908.132641 10.1073/pnas.94.2.514 10.1074/jbc.272.32.20131 10.1158/2643-3230.BCD-20-0093 10.1159/000479863 10.1016/j.freeradbiomed.2017.01.004 10.1038/ng1093 10.1056/NEJMoa1709866 10.3390/molecules26226840 10.1038/sj.onc.1202351 10.1073/pnas.87.19.7555 10.1200/jco.2016.72.1316 10.1038/sj.cgt.7700896 10.1042/BJ20081386 10.1182/blood-2013-12-516245 10.1038/cdd.2017.161 10.1182/blood.2019000847 10.3892/ijo.21.6.1339 10.12659/MSM.916419 10.1074/jbc.273.10.5858 10.1016/j.bbrc.2011.06.176 10.1007/s00280-007-0527-3 10.1016/s0092-8674(00)80416-x 10.1002/humu.22556 10.1158/1535-7163.MCT-06-0433 10.1146/annurev-cancerbio-041916-065808 10.1182/blood.v99.11.4079 10.1042/BSR20180980 10.1177/1534735419845139 10.1016/j.prp.2005.01.002 10.1007/s00204-015-1656-9 10.1056/NEJMoa2012971 10.1200/JCO.19.01056 10.3390/ijms22020656 10.1158/0008-5472.Can-04-3742 10.1182/asheducation-2016.1.580 10.1038/s41598-017-03971-8 10.1056/NEJMoa1609783 10.2220/biomedres.33.57 10.1038/sj.cdd.4401962 10.3389/fonc.2021.642547 10.1038/nrc.2016.36 10.1142/S0192415X15500457 |
ContentType | Journal Article |
Copyright | 2024 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. 2024 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. |
Copyright_xml | – notice: 2024 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. – notice: 2024 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. |
DBID | 24P WIN NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1111/cas.16086 |
DatabaseName | Wiley Online Library (Open Access Collection) Wiley Free Archive PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library (Open Access Collection) url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Abe et al |
EISSN | 1349-7006 |
EndPage | 1332 |
ExternalDocumentID | 10_1111_cas_16086 38279512 CAS16086 |
Genre | researchArticle Journal Article |
GrantInformation_xml | – fundername: Wesco Scientific Promotion Foundation – fundername: Teraoka Scholarship Foundation |
GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 24P 29B 2WC 31~ 36B 3O- 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52W 52X 53G 5GY 5HH 5LA 5VS 66C 7.U 702 7PT 8-0 8-1 8-3 8-4 8-5 8FE 8FH 8UM 930 A01 A03 AAHHS AAZKR ABCQN ABEML ACCFJ ACSCC ACXQS ADBBV ADKYN ADZMN ADZOD AEEZP AENEX AEQDE AFBPY AFEBI AFFNX AFKRA AFPKN AFZJQ AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BBNVY BCNDV BENPR BFHJK BHPHI BY8 CAG CCPQU COF CS3 D-6 D-7 D-E D-F DIK DR2 DU5 E3Z EBS EJD EMB EMOBN EX3 F00 F01 F04 F5P FIJ GODZA GROUPED_DOAJ HCIFZ HF~ HOLLA HYE HZI HZ~ IAO IHR IPNFZ IX1 J0M K.9 K48 KQ8 LC2 LC3 LH4 LK8 LP6 LP7 LW6 M7P MK4 N04 N05 N9A O9- OIG OK1 OVD P2P P2X P2Z P4B P4D PIMPY PROAC Q11 ROL RPM RX1 SJN SUPJJ SV3 TEORI UB1 W8V WIN WOW WQJ WRC WXI X7M XG1 ZXP ~IA ~WT ITC NPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c4206-f7c07c34e22ccb62726fc8cb77dcdb440ce1fdf00d2b7fd20b28e9dde4d541af3 |
IEDL.DBID | RPM |
ISSN | 1347-9032 |
IngestDate | Tue Sep 17 21:29:34 EDT 2024 Sat Oct 26 05:33:32 EDT 2024 Thu Sep 26 15:42:05 EDT 2024 Sat Nov 02 12:29:50 EDT 2024 Sat Aug 24 00:51:58 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | hematologic malignancies alpha‐pinene apoptosis lymphoblastic leukemia, acute, T‐cell T‐cell lymphoma |
Language | English |
License | Attribution-NonCommercial-NoDerivs 2024 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4206-f7c07c34e22ccb62726fc8cb77dcdb440ce1fdf00d2b7fd20b28e9dde4d541af3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-7322-5460 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11007008/ |
PMID | 38279512 |
PQID | 2929066877 |
PQPubID | 23479 |
PageCount | 16 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11007008 proquest_miscellaneous_2929066877 crossref_primary_10_1111_cas_16086 pubmed_primary_38279512 wiley_primary_10_1111_cas_16086_CAS16086 |
PublicationCentury | 2000 |
PublicationDate | April 2024 |
PublicationDateYYYYMMDD | 2024-04-01 |
PublicationDate_xml | – month: 04 year: 2024 text: April 2024 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Hoboken |
PublicationTitle | Cancer science |
PublicationTitleAlternate | Cancer Sci |
PublicationYear | 2024 |
Publisher | John Wiley and Sons Inc |
Publisher_xml | – name: John Wiley and Sons Inc |
References | 2017; 7 2021; 26 2017; 1 2021; 22 1997; 272 2004; 25 2002; 99 2011; 52 2019; 18 2005; 65 2016; 2016 1998; 273 1997; 91 1990; 87 2009; 57 1997; 94 2000 1999; 18 2019; 24 2017; 35 2018; 378 2019; 25 2015; 43 2008; 68 2007; 2 2020; 135 2008; 61 2018; 38 2006; 441 2014; 123 2011; 411 2021; 2 2020; 383 2015; 127 2006; 13 2020; 38 2006; 5 2018; 63 2018; 109 2017; 376 2016; 17 2009; 417 2016; 16 2012; 33 2009; 27 2018; 25 2003; 33 2017; 91 2021; 11 2005; 201 2017; 55 2002; 21 2017 2014; 35 2017; 104 2014; 33 e_1_2_11_32_1 e_1_2_11_55_1 e_1_2_11_30_1 e_1_2_11_57_1 e_1_2_11_36_1 e_1_2_11_51_1 e_1_2_11_13_1 e_1_2_11_34_1 e_1_2_11_53_1 e_1_2_11_11_1 e_1_2_11_29_1 e_1_2_11_6_1 e_1_2_11_27_1 e_1_2_11_4_1 e_1_2_11_48_1 e_1_2_11_20_1 e_1_2_11_45_1 e_1_2_11_47_1 e_1_2_11_24_1 e_1_2_11_41_1 e_1_2_11_8_1 e_1_2_11_22_1 e_1_2_11_43_1 e_1_2_11_17_1 e_1_2_11_15_1 e_1_2_11_38_1 e_1_2_11_19_1 Cooper GM (e_1_2_11_42_1) 2000 e_1_2_11_50_1 e_1_2_11_10_1 e_1_2_11_31_1 e_1_2_11_56_1 e_1_2_11_58_1 e_1_2_11_14_1 e_1_2_11_35_1 e_1_2_11_52_1 e_1_2_11_12_1 e_1_2_11_33_1 e_1_2_11_54_1 Swerdlow SHC E (e_1_2_11_2_1) 2017 e_1_2_11_7_1 e_1_2_11_28_1 e_1_2_11_5_1 e_1_2_11_26_1 e_1_2_11_3_1 e_1_2_11_49_1 e_1_2_11_21_1 e_1_2_11_44_1 e_1_2_11_46_1 e_1_2_11_25_1 e_1_2_11_9_1 e_1_2_11_23_1 e_1_2_11_18_1 e_1_2_11_16_1 Zhou JY (e_1_2_11_40_1) 2004; 25 e_1_2_11_37_1 e_1_2_11_39_1 |
References_xml | – volume: 87 start-page: 7555 year: 1990 end-page: 7559 article-title: p53 mutations in colorectal cancer publication-title: Proc Natl Acad Sci USA – volume: 123 start-page: 2636 year: 2014 end-page: 2644 article-title: How I treat the peripheral T‐cell lymphomas publication-title: Blood – volume: 201 start-page: 109 year: 2005 end-page: 115 article-title: Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines publication-title: Pathol Res Pract – volume: 273 start-page: 5858 year: 1998 end-page: 5868 article-title: DNA double‐stranded breaks induce histone H2AX phosphorylation on serine 139 publication-title: J Biol Chem – volume: 26 year: 2021 article-title: Encapsulation of alpha‐Pinene in delivery systems based on liposomes and cyclodextrins publication-title: Molecules – volume: 99 start-page: 4079 year: 2002 end-page: 4086 article-title: Biologic sequelae of nuclear factor‐kappaB blockade in multiple myeloma: therapeutic applications publication-title: Blood – volume: 27 start-page: 693 year: 2009 end-page: 733 article-title: Regulation and function of NF‐kappaB transcription factors in the immune system publication-title: Annu Rev Immunol – volume: 18 start-page: 943 year: 1999 end-page: 953 article-title: Molecular mechanisms of constitutive NF‐kappaB/Rel activation in Hodgkin/reed‐Sternberg cells publication-title: Oncogene – volume: 411 start-page: 449 year: 2011 end-page: 454 article-title: Alpha‐Pinene isolated from Raddi (Anacardiaceae) induces apoptosis and confers antimetastatic protection in a melanoma model publication-title: Biochem Biophys Res Commun – volume: 13 start-page: 1256 year: 2006 end-page: 1259 article-title: The p53‐Bcl‐2 connection publication-title: Cell Death Differ – volume: 63 start-page: 1 year: 2018 end-page: 7 article-title: Alpha‐Pinene inhibits human prostate cancer growth in a mouse xenograft model publication-title: Chemotherapy – volume: 35 start-page: 756 year: 2014 end-page: 765 article-title: Analysis of TP53 mutation status in human cancer cell lines: a reassessment publication-title: Hum Mutat – volume: 33 start-page: 57 year: 2012 end-page: 61 article-title: Fragrant environment with alpha‐pinene decreases tumor growth in mice publication-title: Biomed Res – volume: 135 start-page: 523 year: 2020 end-page: 533 article-title: The immune landscape and response to immune checkpoint blockade therapy in lymphoma publication-title: Blood – volume: 24 year: 2019 article-title: Development and optimization of alpha‐Pinene‐loaded solid lipid nanoparticles (SLN) using experimental factorial design and dispersion analysis publication-title: Molecules – volume: 38 year: 2018 article-title: Alpha‐pinene regulates miR‐221 and induces G(2)/M phase cell cycle arrest in human hepatocellular carcinoma cells publication-title: Biosci Rep – volume: 272 start-page: 20131 year: 1997 end-page: 20138 article-title: Early growth response‐1‐dependent apoptosis is mediated by p53 publication-title: J Biol Chem – volume: 35 start-page: 2125 year: 2017 end-page: 2132 article-title: Phase II study of the efficacy and safety of Pembrolizumab for relapsed/refractory classic Hodgkin lymphoma publication-title: J Clin Oncol – volume: 11 year: 2021 article-title: The role of the transcription factor EGR1 in cancer publication-title: Front Oncol – volume: 18 year: 2019 article-title: A fragrant environment containing alpha‐Pinene suppresses tumor growth in mice by modulating the hypothalamus/sympathetic nerve/leptin Axis and immune system publication-title: Integr Cancer Ther – volume: 378 start-page: 439 year: 2018 end-page: 448 article-title: Tisagenlecleucel in children and young adults with B‐cell lymphoblastic leukemia publication-title: N Engl J Med – volume: 376 start-page: 836 year: 2017 end-page: 847 article-title: Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia publication-title: N Engl J Med – volume: 441 start-page: 431 year: 2006 end-page: 436 article-title: Nuclear factor‐kappaB in cancer development and progression publication-title: Nature – volume: 2 start-page: 19 year: 2021 end-page: 31 article-title: T‐cell acute lymphoblastic leukemia: a roadmap to targeted therapies publication-title: Blood Cancer Discov – volume: 61 start-page: 727 year: 2008 end-page: 737 article-title: Potentiation of arsenic trioxide cytotoxicity by parthenolide and buthionine sulfoximine in murine and human leukemic cells publication-title: Cancer Chemother Pharmacol – volume: 5 start-page: 2606 year: 2006 end-page: 2612 article-title: Mutation analysis of 24 known cancer genes in the NCI‐60 cell line set publication-title: Mol Cancer Ther – volume: 25 start-page: 480 year: 2004 end-page: 484 article-title: Effect of alpha‐pinene on nuclear translocation of NF‐kappa B in THP‐1 cells publication-title: Acta Pharmacol Sin – volume: 65 start-page: 5133 year: 2005 end-page: 5143 article-title: Early growth response 1 acts as a tumor SuppressorIn vivoandIn vitrovia regulation of p53 publication-title: Cancer Res – volume: 55 start-page: 1553 year: 2017 end-page: 1560 article-title: Phytochemical composition, anti‐inflammatory activity and cytotoxic effects of essential oils from three Pinus spp publication-title: Pharm Biol – volume: 383 start-page: 617 year: 2020 end-page: 629 article-title: Azacitidine and Venetoclax in previously untreated acute myeloid leukemia publication-title: N Engl J Med – volume: 38 start-page: 20 year: 2020 end-page: 28 article-title: Pembrolizumab in relapsed and refractory mycosis Fungoides and Sezary syndrome: a multicenter phase II study publication-title: J Clin Oncol – volume: 13 start-page: 115 year: 2006 end-page: 124 article-title: The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin publication-title: Cancer Gene Ther – volume: 2 year: 2007 article-title: Artesunate induces ROS‐mediated apoptosis in doxorubicin‐resistant T leukemia cells publication-title: PLoS One – volume: 33 start-page: 5655 year: 2014 end-page: 5665 article-title: Mechanisms and consequences of constitutive NF‐kappaB activation in B‐cell lymphoid malignancies publication-title: Oncogene – volume: 16 start-page: 275 year: 2016 end-page: 287 article-title: Mechanism‐driven biomarkers to guide immune checkpoint blockade in cancer therapy publication-title: Nat Rev Cancer – volume: 33 start-page: 357 year: 2003 end-page: 365 article-title: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential publication-title: Nat Genet – volume: 68 start-page: 8031 year: 2008 end-page: 8038 article-title: Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs publication-title: Cancer Res – volume: 104 start-page: 144 year: 2017 end-page: 164 article-title: Reactive oxygen species and cancer paradox: to promote or to suppress? publication-title: Free Radic Biol Med – volume: 127 start-page: 332 year: 2015 end-page: 338 article-title: Anti‐tumor effect of alpha‐pinene on human hepatoma cell lines through inducing G2/M cell cycle arrest publication-title: J Pharmacol Sci – year: 2000 – volume: 91 start-page: 677 year: 2017 end-page: 687 article-title: Human metabolism of alpha‐pinene and metabolite kinetics after oral administration publication-title: Arch Toxicol – volume: 17 start-page: 1283 year: 2016 end-page: 1294 article-title: Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial publication-title: Lancet Oncol – volume: 7 start-page: 3782 year: 2017 article-title: Dietary mastic oil extracted from var. chia suppresses tumor growth in experimental colon cancer models publication-title: Sci Rep – volume: 91 start-page: 325 year: 1997 end-page: 334 article-title: DNA damage‐induced phosphorylation of p53 alleviates inhibition by MDM2 publication-title: Cell – volume: 22 year: 2021 article-title: Alpha‐Pinene enhances the anticancer activity of natural killer cells via ERK/AKT pathway publication-title: Int J Mol Sci – volume: 21 start-page: 1339 year: 2002 end-page: 1345 article-title: Vincristine induced apoptosis in acute lymphoblastic leukaemia cells: a mitochondrial controlled pathway regulated by reactive oxygen species? publication-title: Int J Oncol – volume: 94 start-page: 514 year: 1997 end-page: 519 article-title: Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress publication-title: Proc Natl Acad Sci USA – volume: 25 start-page: 27 year: 2018 end-page: 36 article-title: The BCL‐2 arbiters of apoptosis and their growing role as cancer targets publication-title: Cell Death Differ – volume: 1 start-page: 79 year: 2017 end-page: 98 article-title: The two faces of reactive oxygen species in cancer publication-title: Annu Rev Cancer Biol – volume: 52 start-page: 342 year: 2011 end-page: 350 article-title: Cycloheximide suppresses radiation‐induced apoptosis in MOLT‐4 cells with Arg72 variant of p53 through translational inhibition of p53 accumulation publication-title: J Radiat Res – volume: 57 start-page: 6636 year: 2009 end-page: 6641 article-title: Protective effects of the essential oil of Salvia fruticosa and its constituents on astrocytic susceptibility to hydrogen peroxide‐induced cell death publication-title: J Agric Food Chem – volume: 417 start-page: 1 year: 2009 end-page: 13 article-title: How mitochondria produce reactive oxygen species publication-title: Biochem J – year: 2017 – volume: 109 start-page: 3376 year: 2018 end-page: 3382 article-title: Tumor suppressive role for kinases phosphorylating p53 in DNA damage‐induced apoptosis publication-title: Cancer Sci – volume: 25 start-page: 6631 year: 2019 end-page: 6638 article-title: Alpha‐Pinene induces apoptotic cell death via caspase activation in human ovarian cancer cells publication-title: Med Sci Monit – volume: 2016 start-page: 580 year: 2016 end-page: 588 article-title: T‐cell acute lymphoblastic leukemia publication-title: Hematology Am Soc Hematol Educ Program – volume: 43 start-page: 731 year: 2015 end-page: 742 article-title: Alpha‐Pinene exhibits anti‐inflammatory activity through the suppression of MAPKs and the NF‐kappaB pathway in mouse peritoneal macrophages publication-title: Am J Chin Med – ident: e_1_2_11_52_1 doi: 10.1016/S1470-2045(16)30167-X – ident: e_1_2_11_6_1 doi: 10.1080/13880209.2017.1309555 – volume-title: WHO Classification of Tumours of Haematopoietic & Lymphoid Tissues year: 2017 ident: e_1_2_11_2_1 contributor: fullname: Swerdlow SHC E – ident: e_1_2_11_34_1 doi: 10.1269/jrr.10151 – volume-title: The Cell: A Molecular Approach year: 2000 ident: e_1_2_11_42_1 contributor: fullname: Cooper GM – ident: e_1_2_11_46_1 doi: 10.1158/0008-5472.CAN-08-1490 – ident: e_1_2_11_58_1 doi: 10.3390/molecules24152683 – ident: e_1_2_11_26_1 doi: 10.1111/cas.13792 – ident: e_1_2_11_38_1 doi: 10.1038/onc.2013.565 – ident: e_1_2_11_48_1 doi: 10.1371/journal.pone.0000693 – ident: e_1_2_11_43_1 doi: 10.1021/jf901162f – ident: e_1_2_11_37_1 doi: 10.1038/nature04870 – ident: e_1_2_11_16_1 doi: 10.1016/j.jphs.2015.01.008 – ident: e_1_2_11_39_1 doi: 10.1146/annurev.immunol.021908.132641 – ident: e_1_2_11_19_1 doi: 10.1073/pnas.94.2.514 – ident: e_1_2_11_24_1 doi: 10.1074/jbc.272.32.20131 – ident: e_1_2_11_5_1 doi: 10.1158/2643-3230.BCD-20-0093 – ident: e_1_2_11_9_1 doi: 10.1159/000479863 – ident: e_1_2_11_44_1 doi: 10.1016/j.freeradbiomed.2017.01.004 – ident: e_1_2_11_51_1 doi: 10.1038/ng1093 – ident: e_1_2_11_15_1 doi: 10.1056/NEJMoa1709866 – ident: e_1_2_11_41_1 doi: 10.3390/molecules26226840 – ident: e_1_2_11_35_1 doi: 10.1038/sj.onc.1202351 – ident: e_1_2_11_31_1 doi: 10.1073/pnas.87.19.7555 – volume: 25 start-page: 480 year: 2004 ident: e_1_2_11_40_1 article-title: Effect of alpha‐pinene on nuclear translocation of NF‐kappa B in THP‐1 cells publication-title: Acta Pharmacol Sin contributor: fullname: Zhou JY – ident: e_1_2_11_53_1 doi: 10.1200/jco.2016.72.1316 – ident: e_1_2_11_22_1 doi: 10.1038/sj.cgt.7700896 – ident: e_1_2_11_18_1 doi: 10.1042/BJ20081386 – ident: e_1_2_11_4_1 doi: 10.1182/blood-2013-12-516245 – ident: e_1_2_11_29_1 doi: 10.1038/cdd.2017.161 – ident: e_1_2_11_55_1 doi: 10.1182/blood.2019000847 – ident: e_1_2_11_47_1 doi: 10.3892/ijo.21.6.1339 – ident: e_1_2_11_17_1 doi: 10.12659/MSM.916419 – ident: e_1_2_11_21_1 doi: 10.1074/jbc.273.10.5858 – ident: e_1_2_11_8_1 doi: 10.1016/j.bbrc.2011.06.176 – ident: e_1_2_11_49_1 doi: 10.1007/s00280-007-0527-3 – ident: e_1_2_11_27_1 doi: 10.1016/s0092-8674(00)80416-x – ident: e_1_2_11_30_1 doi: 10.1002/humu.22556 – ident: e_1_2_11_33_1 doi: 10.1158/1535-7163.MCT-06-0433 – ident: e_1_2_11_45_1 doi: 10.1146/annurev-cancerbio-041916-065808 – ident: e_1_2_11_36_1 doi: 10.1182/blood.v99.11.4079 – ident: e_1_2_11_20_1 doi: 10.1042/BSR20180980 – ident: e_1_2_11_11_1 doi: 10.1177/1534735419845139 – ident: e_1_2_11_32_1 doi: 10.1016/j.prp.2005.01.002 – ident: e_1_2_11_57_1 doi: 10.1007/s00204-015-1656-9 – ident: e_1_2_11_13_1 doi: 10.1056/NEJMoa2012971 – ident: e_1_2_11_54_1 doi: 10.1200/JCO.19.01056 – ident: e_1_2_11_12_1 doi: 10.3390/ijms22020656 – ident: e_1_2_11_25_1 doi: 10.1158/0008-5472.Can-04-3742 – ident: e_1_2_11_3_1 doi: 10.1182/asheducation-2016.1.580 – ident: e_1_2_11_7_1 doi: 10.1038/s41598-017-03971-8 – ident: e_1_2_11_14_1 doi: 10.1056/NEJMoa1609783 – ident: e_1_2_11_10_1 doi: 10.2220/biomedres.33.57 – ident: e_1_2_11_28_1 doi: 10.1038/sj.cdd.4401962 – ident: e_1_2_11_23_1 doi: 10.3389/fonc.2021.642547 – ident: e_1_2_11_56_1 doi: 10.1038/nrc.2016.36 – ident: e_1_2_11_50_1 doi: 10.1142/S0192415X15500457 |
SSID | ssj0036494 |
Score | 2.4815369 |
Snippet | T‐cell acute leukemia and lymphoma have a poor prognosis. Although new therapeutic agents have been developed, their therapeutic effects are suboptimal.... T-cell acute leukemia and lymphoma have a poor prognosis. Although new therapeutic agents have been developed, their therapeutic effects are suboptimal.... Abstract T‐cell acute leukemia and lymphoma have a poor prognosis. Although new therapeutic agents have been developed, their therapeutic effects are... |
SourceID | pubmedcentral proquest crossref pubmed wiley |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 1317 |
SubjectTerms | alpha‐pinene apoptosis hematologic malignancies lymphoblastic leukemia, acute, T‐cell Original ORIGINAL ARTICLES T‐cell lymphoma |
SummonAdditionalLinks | – databaseName: Wiley Online Library (Open Access Collection) dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LS8NAEB5qBfEivo0vonjwEkj2kd3gqRRLESqCLfQWuo9gD6alj7s_wb_iH_FH-EvcSZrSUgRvGzLZbGZ3dr_dzHwDcJcRh4spNQFLmAqYtjxQrhgkIdfccmokx0DhznPc7rGnPu_X4KGKhSn5IZYHbmgZxXyNBj5Q0xUjx5RgUewQ-RZsI2MM-vMR9lJNwzRmSZnRlgn3ZkoWtELoxrN8dH0x2kCYm46SqwC2WIFa-7C3gI5-o-zrA6jZ_BB2Oouf40fAGhhyO38fTXyMVsCkEP4o87-_fj4-x04it_4w97vuCk_r_UJyegy91mO32Q4WSRECzYjb_WdCh0JTZgnRWsVEkDjTUishjDaKsVDbKDNZGBqiRGZIqIi0iZvEmOEsGmT0BOr5KLdn4Avkjo9kIrk0LNEct0rOpCNDWWhdtR7cVtpJxyX3RVrtGZwK00KFHtxUekvdyMQPGOR2NJ-mJEEq-VgK4cFpqcdlNVQS4bAd8UCuaXgpgKzX63fy4VvBfo0cd8IhFw_ui874u2lps_FaFM7_L3oBu8TBltI35xLqs8ncXjnYMVPXxfD6BRr01Js priority: 102 providerName: Wiley-Blackwell |
Title | Antitumor activity of α‐pinene in T‐cell tumors |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcas.16086 https://www.ncbi.nlm.nih.gov/pubmed/38279512 https://search.proquest.com/docview/2929066877 https://pubmed.ncbi.nlm.nih.gov/PMC11007008 |
Volume | 115 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwEB1RkBAXxE5YqoA4cAlNvMTOsVQghFRUsUjcIrxEVKJpVeidT-BX-BE-gi9h7DSICnHhEjmKZTvjif3GmXkDcFQQxMWUmohlTEVMWx4pLEZZzDW3nBrJXaBw9yq9uGOX9_x-DtI6FsY77WvVPymfBidl_9H7Vo4GulX7ibV63Y6jORO4ebUa0EANrW30av2lKcuqVLZMYJeUTPmEnP-OSyOWpIjil2CRSiIQXpDZDekXyvztLPkTxPpd6HwFlqfwMWxXw1yFOVuuwWJ3-oN8HVjbhd1OBsNx6CIWXGKIcFiEH--fr28jrFHasF-Gt3jnTuxDX_N5A-7Oz247F9E0MUKkGYnTqBA6FpoyS4jWKiWCpIWWWglhtFGMxdomhSni2BAlCkNiRaTNcCFjhrPkoaCbMF8OS7sNoXD88YnMJJeGZZo7cwk_68RQFltsNoDDWjr5qOK_yGu7AaWZe2kGcFDLLUftdC_wUNrh5DknmaOTT6UQAWxVcvxupp6AAOSMhL8rOObr2SeoEJ4Bu1aAAI79ZPw9tLzTvvGFnf_3sgtLBKFM5a-zB_Mv44ndRyjyoprQIKzXhIXTs6veddMb9O56TZpeJ78AgXHiJA |
link.rule.ids | 230,315,730,783,787,867,888,1378,11575,27937,27938,33758,46065,46307,46489,46731,50827,50936,53805,53807 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3JTsMwEB0VKgEXxE5YA-LAJVLiJXYkLhWiKku50CLEJSK2I3ogQbS98wn8Cj_CR_AljLNUrRASN0eZOM7YYz9PPG8ATlKCuJhS7bGIJR5ThnsJFr3I54obTrXkNlC4ext2-uzqgT804KyOhSn5ISYON2sZxXxtDdw6pKes3OYEC0KE5HPQxGWP4vhutu77j_16JqYhi8qktkzgyympmIXsSZ7Jw7Pr0S-Q-fus5DSGLRah9gosV-jRbZXdvQoNk63BQrf6P74OrGWjbscv-ZtrAxZsXgg3T92vz-_3j1eUyIw7yNweXlmHvVtIDjeg377onXe8Ki-CpxjxQy8VyheKMkOIUklIBAlTJVUihFY6YcxXJkh16vuaJCLVxE-INBHOY0xzFjyldBPmszwz2-AKSx8fyEhyqVmkuN0toVUHmjLfYLUOHNfaiV9L-ou43jagCuNChQ4c1XqLcXDaD3jKTD4exiSybPKhFMKBrVKPk2qoJALhHXFAzmh4ImCJr2fvZIPnggDb0twJBC8OnBad8XfT4vPWXVHY-b_oISx2et2b-Oby9noXlgiimPKozh7Mj97GZh9RyCg5qAbbD8We2dU |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NSsQwEB50BfEi_lt_q3jwUmiTSZPiaVld_EdQwVux-UEPdhd17z6Cr-KL-BA-iZN2u7iI4C2l0zSdZJIv6cw3AHuOES7m3ESYYRGhtiIqqBhlsdDCCm6U8IHCF5fp8S2e3om7CThoYmFqfojRgZu3jGq-9gbeN-6HkfuUYElKiHwSppBguPfnY3jVTMM8xazOaIuS3szZkFbIu_GMHh1fjH4hzN-Okj8BbLUCdedgdggdw3bd1_MwYcsFmL4Y_hxfBGz7kNvBU-859NEKPilE2HPh58fX23ufJEobPpbhDV350_qwknxZgtvu0U3nOBomRYg0Mtr9O6ljqTlaxrQuUiZZ6rTShZRGmwIx1jZxxsWxYYV0hsUFUzajSQyNwOTe8WVolb3SrkIoPXd8ojIllMFMC79VIpNODMfYUrUB7Dbayfs190Xe7BlIhXmlwgB2Gr3lNDL9B9yXtjd4yVnmqeRTJWUAK7UeR9VwxSRhOxaAGtPwSMCzXo_fKR8fKvZrz3EnCbkEsF91xt9Nyzvt66qw9n_RbZi-Ouzm5yeXZ-swwwjB1G46G9B6fR7YTUIgr8VWNdK-AWea1y8 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antitumor+activity+of+%CE%B1-pinene+in+T-cell+tumors&rft.jtitle=Cancer+science&rft.au=Abe%2C+Masaya&rft.au=Asada%2C+Noboru&rft.au=Kimura%2C+Maiko&rft.au=Fukui%2C+Chie&rft.date=2024-04-01&rft.eissn=1349-7006&rft.volume=115&rft.issue=4&rft.spage=1317&rft.epage=1332&rft_id=info:doi/10.1111%2Fcas.16086&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-9032&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-9032&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-9032&client=summon |